574 related articles for article (PubMed ID: 11858800)
1. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
2. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; Wybren De Jong
Hypertension; 1999 May; 33(5):1201-6. PubMed ID: 10334812
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and renal effects of central administration of a mineralocorticoid receptor antagonist in conscious female rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 1999 Dec; 385(2-3):199-202. PubMed ID: 10607876
[TBL] [Abstract][Full Text] [Related]
4. Influence of sodium intake on the cardiovascular and renal effects of brain mineralocorticoid receptor blockade in normotensive rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
J Hypertens; 2002 Sep; 20(9):1829-34. PubMed ID: 12195126
[TBL] [Abstract][Full Text] [Related]
5. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
Hypertension; 2001 Oct; 38(4):902-6. PubMed ID: 11641306
[TBL] [Abstract][Full Text] [Related]
6. Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats.
Van den Berg DT; de Kloet ER; de Jong W
Am J Physiol; 1994 Dec; 267(6 Pt 1):E927-33. PubMed ID: 7810636
[TBL] [Abstract][Full Text] [Related]
7. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
[TBL] [Abstract][Full Text] [Related]
8. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Pham I; el Amrani AI; Fournié-Zaluski MC; Corvol P; Roques B; Michel JB
J Cardiovasc Pharmacol; 1992 Dec; 20(6):847-57. PubMed ID: 1282584
[TBL] [Abstract][Full Text] [Related]
9. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
Nishimura M; Ohtsuka K; Sakamoto M; Nanbu A; Takahashi H; Yoshimura M
J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
[TBL] [Abstract][Full Text] [Related]
10. Increased renal atrial natriuretic peptide synthesis in rats with deoxycorticosterone acetate-salt treatment.
Lee YJ; Shin SJ; Tan MS; Hsieh TJ; Tsai JH
Am J Physiol; 1996 Oct; 271(4 Pt 2):F779-89. PubMed ID: 8898007
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
12. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats.
David FL; Carvalho MH; Cobra AL; Nigro D; Fortes ZB; Rebouças NA; Tostes RC
Hypertension; 2001 Sep; 38(3 Pt 2):692-6. PubMed ID: 11566958
[TBL] [Abstract][Full Text] [Related]
13. Further studies in deoxycorticosterone acetate treated rats: brain content of mineralocorticoid and glucocorticoid receptors and effect of steroid antagonists on salt intake.
Vallee SM; Grillo CA; Gonzalez S; Cosen-Binker L; de Kloet ER; McEwen BS; De Nicola AF
Neuroendocrinology; 1995 Feb; 61(2):117-24. PubMed ID: 7753331
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure and renal responses to synthetic rat atrial natriuretic factor in deoxycorticosterone acetate-salt hypertension.
Kohzuki M; Abe K; Yasujima M; Kasai Y; Hiwatari M; Kanazawa M; Sato M; Omata K; Kudo K; Takeuchi K
Tohoku J Exp Med; 1989 Apr; 157(4):301-11. PubMed ID: 2525826
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
[TBL] [Abstract][Full Text] [Related]
16. No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension.
Uijl E; Ren L; Mirabito Colafella KM; van Veghel R; Garrelds IM; Domenig O; Poglitsch M; Zlatev I; Kim JB; Huang S; Melton L; Hoorn EJ; Foster D; Danser AHJ
Clin Sci (Lond); 2021 Jan; 135(2):259-274. PubMed ID: 33404046
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
18. Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats.
Dai SY; Peng W; Zhang YP; Li JD; Shen Y; Sun XF
J Neuroinflammation; 2015 Mar; 12():47. PubMed ID: 25885968
[TBL] [Abstract][Full Text] [Related]
19. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
[TBL] [Abstract][Full Text] [Related]
20. Cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice.
Gross V; Lippoldt A; Bohlender J; Bader M; Hansson A; Luft FC
J Am Soc Nephrol; 1998 Mar; 9(3):346-54. PubMed ID: 9513896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
